ChemicalBook--->CAS DataBase List--->216974-75-3

216974-75-3

216974-75-3 Structure

216974-75-3 Structure
IdentificationBack Directory
[Name]

Avastin
[CAS]

216974-75-3
[Synonyms]

Avastin
Avastatin
Bevacizumab
Rhumab-vegf
Bevacituzumab
Unii-2S9zzm9Q9v
Bevacizumab USP/EP/BP
Bevacizumab (Avastin)
BevacizuMab [USAN:INN]
Bevacizumab(anti-VEGF)
Anti-vegf monoclonal antibody
Bevacizumab - 25mg/ml solution in PBS
Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhumab-vegf gamma1-chain), disulfide with human-mouse monoclonal rhumab-vegf light chain, dimer
[EINECS(EC#)]

200-160-3
[Molecular Formula]

C6638H10160N1720O2108S44
[MDL Number]

MFCD08272721
Chemical PropertiesBack Directory
[storage temp. ]

Store at -80°C
[solubility ]

Soluble in DMSO
Safety DataBack Directory
[Hazardous Substances Data]

216974-75-3(Hazardous Substances Data)
Hazard InformationBack Directory
[Description]

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (Kd=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m2 i.v., 5-fluorouracil 500 mg/ m2 i.v., and leucovorin 20 mg/m2 i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.
[Originator]

Genentech (US)
[Brand name]

Avastin
[Clinical Use]

Monoclonal antibody:

Treatment of colorectal cancer

Treatment of breast cancer

Treatment of renal cell carcinoma

Treatment of lung cancer

Treatment of ovarian, fallopian tube or peritoneal cancer
[Enzyme inhibitor]

This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.
[target]

Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents.  Bevacizumab is a humanised recombinant antibody that prevents vascular  endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.
[Drug interactions]

Potentially hazardous interactions with other drugs
Bisphosphonates: increased risk of osteonecrosis of the jaw.
Cytotoxics: avoid with panitumumab.
Vaccines: risk of generalised infections with live vaccines - avoid.
[Metabolism]

Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.
216974-75-3 suppliers list
Company Name: Shanghai Minbiotech Co., Ltd.
Tel: +8617315815539 , +8617315815539
Website: www.chemicalbook.com/ShowSupplierProductsList516870/0.htm
Company Name: Biochempartner
Tel: 0086-13720134139
Website: www.biochempartner.com
Company Name: Shenzhen Nexconn Pharmatechs Ltd
Tel: +86-755-89396905 +86-15013857715 , +86-15013857715
Website: https://www.chemicalbook.com/ShowSupplierProductsList31188/0.htm
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Website: www.chemicalbook.com/ShowSupplierProductsList1549548/0.htm
Company Name: Hubei Ipure Biology Co., Ltd
Tel: +8613367258412 , +8613367258412
Website: www.ipurechemical.com
Company Name: HONG KONG IPURE BIOLOGY CO.,LIMITED
Tel: 86 18062405514 18062405514 , 18062405514
Website: www.chemicalbook.com/ShowSupplierProductsList1523002/0_EN.htm
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel: +86-029-89586680 +86-18192503167 , +86-18192503167
Website: www.dideu.com
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250 , +86-15129568250
Website: www.dideu.com
Company Name: AFINE CHEMICALS LIMITED
Tel: 0571-85134551
Website: www.afinechem.com/index.html
Company Name: Wuhan Fortuna Chemical Co., Ltd
Tel: +86-27-59207850 +86-13986145403 , +86-13986145403
Website: www.fortunachem.com/
Company Name: Baoji Guokang Healthchem co.,ltd
Tel: +8615604608665 15604608665 , 15604608665
Website: www.gk-bio.com
Company Name: Hefei Hirisun Pharmatech Co., Ltd
Tel: +8615056975894 , +8615056975894
Website: www.hirisunpharm.com
Company Name: Zhejiang J&C Biological Technology Co.,Limited
Tel: +1-2135480471 +1-2135480471 , +1-2135480471
Website: https://www.sarms4muscle.com
Company Name: Hangzhou Huarong Pharm Co., Ltd.
Tel: 571-86758373 +8613588754946 , +8613588754946
Website: https://www.huarongpharm.com/
Company Name: Hangzhou Proserre Chemical Co.,Ltd.
Tel: +86-571-86088112
Website: https://www.proserre.com/
Company Name: LEAP CHEM CO., LTD.
Tel: +86-852-30606658
Website: www.leapchem.com
Company Name: Nantong HI-FUTURE Biology Co., Ltd.
Tel: +undefined18051384581 , +undefined18051384581
Website: https://www.chemhifuture.com/
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354
Website: https://www.targetmol.com/
Tags:216974-75-3 Related Product Information
331731-18-1 815610-63-0 946414-94-4 945721-28-8 242138-07-4 1374853-91-4 923950-08-7 170277-31-3 174722-31-7 95058-81-4 76-25-5 610798-31-7 347396-82-1 1256937-27-5 947687-13-0 477202-00-9 219685-50-4